Health Affairs, 25, no. 5 (2006): 1347-1352
doi: 10.1377/hlthaff.25.5.1347
© 2006 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Full Text (HTML)
* Reprint (PDF)
* Online Exhibit
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via Web of Science (3)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Watkins, J. B.
* Articles by Sullivan, S. D.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Watkins, J. B.
* Articles by Sullivan, S. D.
Related Collections
* Access To Care
* Insurance Coverage
* Managed Care
* Managed Care - Consumers
* Business Of Health
* Pharmaceuticals
* Chronic Care
* Quality Of Care
* Research And Technology
* Health Spending
* Consumer Issues
* Insurance Market

Specialty Drugs

PERSPECTIVE

Managing Biotechnology In A Network-Model Health Plan: A U.S. Private Payer Perspective

John B. Watkins, Sanchita Roy Choudhury, Ed Wong and Sean D. Sullivan

Emerging biotechnology poses challenges to payers, including access, coverage, reimbursement, patient selection, and affordability. Premera Blue Cross, a private regional health plan, developed an integrated cross-functional approach to managing biologics, built around a robust formulary process that is fast, flexible, fair, and transparent to stakeholders. Results are monitored by cost and use reporting from merged pharmacy and medical claims. Utilization management and case management strategies will integrate with specialty pharmacy programs to improve outcomes and cost-effectiveness. Creative approaches to provider reimbursement can align providers’ incentives with those of the plan. Redesign of member benefits can also encourage appropriate use of biotechnology.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?